A Solid Tumor Study for Long Term Treatment of Cancer Patients Who Participated in Adagrasib Studies
August 17, 2026 updated by: Mirati Therapeutics Inc.
Solid Tumor Study for Long Term Treatment of Cancer Patients Who Have Participated in BMS Parent Studies Investigating Adagrasib (BMS-986503)
This is an open-label, solid tumor, continuation, rollover trial which enrolls participants from ongoing BMS parent studies that evaluated adagrasib (MRTX849, BMS-986503) either as monotherapy or in combination with other cancer therapies in patients with non-small cell lung cancer (NSCLC), colorectal cancer (CRC) and other advanced solid tumors.
Study Overview
Status
Recruiting
Conditions
Study Type
Interventional
Enrollment (Estimated)
170
Phase
- Phase 2
Contacts and Locations
This section provides the contact details for those conducting the study, and information on where this study is being conducted.
Study Contact
- Name: First line of the email MUST contain NCT # and Site #.
Study Contact Backup
- Name: BMS Clinical Trials Contact Center www.BMSClinicalTrials.com
- Phone Number: 855-907-3286
- Email: Clinical.Trials@bms.com
Study Locations
-
-
New South Wales
-
St Leonards, New South Wales, Australia, 2065
- Not yet recruiting
- Local Institution - 0093
-
Contact:
- Site 0093
-
-
-
-
-
Ghent, Belgium, 9000
- Not yet recruiting
- Local Institution - 0033
-
Contact:
- Site 0033
-
-
-
-
British Columbia
-
Vancouver, British Columbia, Canada, V5Z 4E6
- Not yet recruiting
- Local Institution - 0072
-
Contact:
- Site 0072
-
-
-
-
-
Xi'an, China, 710061
- Not yet recruiting
- Local Institution - 0041
-
Contact:
- Site 0041
-
-
Beijing Municipality
-
Beijing, Beijing Municipality, China, 100142
- Not yet recruiting
- Local Institution - 0037
-
Contact:
- Site 0037
-
-
Fujian
-
Xiamen, Fujian, China, 361003
- Not yet recruiting
- Local Institution - 0045
-
Contact:
- Site 0045
-
-
Henan
-
Zhengzhou, Henan, China, 450008
- Not yet recruiting
- Local Institution - 0042
-
Contact:
- Site 0042
-
-
Hunan
-
Changsha, Hunan, China, 410031
- Not yet recruiting
- Local Institution - 0038
-
Contact:
- Site 0038
-
-
Jiangsu
-
Nanjing, Jiangsu, China, 210012
- Not yet recruiting
- Local Institution - 0046
-
Contact:
- Site 0046
-
-
Jiangxi
-
Nanchang, Jiangxi, China, 330006
- Not yet recruiting
- Local Institution - 0048
-
Contact:
- Site 0048
-
-
Liaoning
-
Shenyang, Liaoning, China, 110001
- Not yet recruiting
- Local Institution - 0049
-
Contact:
- Site 0049
-
-
Shandong
-
Jinan, Shandong, China, 250117
- Not yet recruiting
- Local Institution - 0039
-
Contact:
- Site 0039
-
Linyi, Shandong, China, 276000
- Not yet recruiting
- Local Institution - 0047
-
Contact:
- Site 0047
-
-
Shanghai Municipality
-
Shanghai, Shanghai Municipality, China, 200032
- Not yet recruiting
- Local Institution - 0043
-
Contact:
- Site 0043
-
-
Sichuan
-
Chengdu, Sichuan, China, 610041
- Not yet recruiting
- Local Institution - 0040
-
Contact:
- Site 0040
-
-
Zhejiang
-
Hangzhou, Zhejiang, China, 310022
- Not yet recruiting
- Local Institution - 0044
-
Contact:
- Site 0044
-
-
-
-
-
Créteil, France, 94010
- Not yet recruiting
- Local Institution - 0085
-
Contact:
- Site 0085
-
Marseille, France, 13915
- Not yet recruiting
- Local Institution - 0059
-
Contact:
- Site 0059
-
Quimper, France, 29000
- Not yet recruiting
- Local Institution - 0058
-
Contact:
- Site 0058
-
Saint-Mandé, France, 94163
- Not yet recruiting
- Local Institution - 0078
-
Contact:
- Site 0078
-
Tours, France, 37032
- Not yet recruiting
- Local Institution - 0077
-
Contact:
- Site 0077
-
-
Alpes-Maritimes
-
Nice, Alpes-Maritimes, France, 06000
- Not yet recruiting
- Local Institution - 0076
-
Contact:
- Site 0076
-
Nice, Alpes-Maritimes, France, 06189
- Not yet recruiting
- Local Institution - 0086
-
Contact:
- Site 0086
-
-
Alsace
-
Strasbourg, Alsace, France, 67091
- Not yet recruiting
- Local Institution - 0074
-
Contact:
- Site 0074
-
-
Aquitaine
-
Pessac, Aquitaine, France, 33600
- Not yet recruiting
- Local Institution - 0103
-
Contact:
- Site 0103
-
-
Doubs
-
Besançon, Doubs, France, 25000
- Not yet recruiting
- Local Institution - 0091
-
Contact:
- Site 0091
-
-
Isère
-
La Tronche, Isère, France, 38700
- Not yet recruiting
- Local Institution - 0065
-
Contact:
- Site 0065
-
-
Loire-Atlantique
-
Saint-Herblain, Loire-Atlantique, France, 44800
- Not yet recruiting
- Local Institution - 0063
-
Contact:
- Site 0063
-
Saint-Herblain, Loire-Atlantique, France, 44805
- Not yet recruiting
- Local Institution - 0050
-
Contact:
- Site 0050
-
-
Maine-et-Loire
-
Angers, Maine-et-Loire, France, 49055
- Not yet recruiting
- Local Institution - 0032
-
Contact:
- Site 0032
-
-
Rhône
-
Bron, Rhône, France, 69677
- Not yet recruiting
- Local Institution - 0090
-
Contact:
- Site 0090
-
Gleizé, Rhône, France, 69400
- Not yet recruiting
- Local Institution - 0075
-
Contact:
- Site 0075
-
-
Vienne
-
Poitiers, Vienne, France, 86021
- Not yet recruiting
- Local Institution - 0051
-
Contact:
- Site 0051
-
-
Île-de-France Region
-
Paris, Île-de-France Region, France, 75014
- Not yet recruiting
- Local Institution - 0061
-
Contact:
- Site 0061
-
-
-
-
-
München, Germany, 81737
- Not yet recruiting
- Local Institution - 0012
-
Contact:
- Site 0012
-
-
-
-
-
Attiki, Greece, 18547
- Not yet recruiting
- Local Institution - 0022
-
Contact:
- Site 0022
-
Thessaloniki, Greece, 54639
- Not yet recruiting
- Local Institution - 0087
-
Contact:
- Site 0087
-
-
Attikí
-
Athens, Attikí, Greece, 115 28
- Not yet recruiting
- Local Institution - 0081
-
Contact:
- Site 0081
-
-
-
-
-
Budapest, Hungary, 1121
- Not yet recruiting
- Local Institution - 0089
-
Contact:
- Site 0089
-
Budapest, Hungary, 1122
- Not yet recruiting
- Local Institution - 0067
-
Contact:
- Site 0067
-
-
-
-
-
Haifa, Israel, 31048
- Not yet recruiting
- Local Institution - 0119
-
Contact:
- Site 0119
-
Tel Aviv, Israel, 6423906
- Not yet recruiting
- Local Institution - 0106
-
Contact:
- Site 0106
-
-
Jerusalem
-
Jerusalem, Jerusalem, Israel, 9103102
- Not yet recruiting
- Local Institution - 0055
-
Contact:
- Site 0055
-
-
-
-
-
Bologna, Italy, 40138
- Not yet recruiting
- Local Institution - 0053
-
Contact:
- Site 0053
-
Florence, Italy, 50139
- Not yet recruiting
- Local Institution - 0054
-
Contact:
- Site 0054
-
Meldola, Italy, 47014
- Not yet recruiting
- Local Institution - 0052
-
Contact:
- Site 0052
-
Milan, Italy, 20141
- Not yet recruiting
- Local Institution - 0021
-
Contact:
- Site 0021
-
Milan, Italy, 20141
- Not yet recruiting
- Local Institution - 0107
-
Contact:
- Site 0107
-
Orbassano, Italy, 10043
- Not yet recruiting
- Local Institution - 0020
-
Contact:
- Site 0020
-
Pesaro, Italy, 61122
- Not yet recruiting
- Local Institution - 0079
-
Contact:
- Site 0079
-
Roma, Italy, 00168
- Not yet recruiting
- Local Institution - 0031
-
Contact:
- Site 0031
-
Terni (Perugia), Italy, 6156
- Not yet recruiting
- Local Institution - 0026
-
Contact:
- Site 0026
-
-
Roma
-
Rome, Roma, Italy, 00144
- Not yet recruiting
- Local Institution - 0019
-
Contact:
- Site 0019
-
-
-
-
Ehime
-
Tōon, Ehime, Japan, 791-0295
- Not yet recruiting
- Local Institution - 0110
-
Contact:
- Site 0110
-
-
-
-
-
Amsterdam, Netherlands, 1006 BE
- Not yet recruiting
- Local Institution - 0034
-
Contact:
- Site 0034
-
Harderwijk, Netherlands, 3844 DG
- Not yet recruiting
- Local Institution - 0035
-
Contact:
- Site 0035
-
Utrecht, Netherlands, 3543 AZ
- Not yet recruiting
- Local Institution - 0071
-
Contact:
- Site 0071
-
-
North Brabant
-
Breda, North Brabant, Netherlands, 4818 CK
- Not yet recruiting
- Local Institution - 0056
-
Contact:
- Site 0056
-
-
-
-
-
Gdansk, Poland, 80-214
- Not yet recruiting
- Local Institution - 0102
-
Contact:
- Site 0102
-
-
-
-
Lisbon District
-
Lisbon, Lisbon District, Portugal, 1099-023
- Not yet recruiting
- Local Institution - 0014
-
Contact:
- Site 0014
-
-
-
-
Dolj
-
Craiova, Dolj, Romania, 200746
- Not yet recruiting
- Local Institution - 0060
-
Contact:
- Site 0060
-
-
-
-
Central Singapore
-
Singapore, Central Singapore, Singapore, 168583
- Not yet recruiting
- Local Institution - 0088
-
Contact:
- Site 0088
-
-
-
-
-
Gyeonggi-do, South Korea, 410-769
- Not yet recruiting
- Local Institution - 0069
-
Contact:
- Site 0069
-
Seoul, South Korea, 06351
- Not yet recruiting
- Local Institution - 0070
-
Contact:
- Site 0070
-
Seoul, South Korea, 120-752
- Not yet recruiting
- Local Institution - 0068
-
Contact:
- Site 0068
-
-
-
-
-
Barcelona, Spain, 08035
- Not yet recruiting
- Local Institution - 0029
-
Contact:
- Site 0029
-
Córdoba, Spain, 14004
- Not yet recruiting
- Local Institution - 0027
-
Contact:
- Site 0027
-
Madrid, Spain, 28007
- Not yet recruiting
- Local Institution - 0083
-
Contact:
- Site 0083
-
Madrid, Spain, 28040
- Not yet recruiting
- Local Institution - 0015
-
Contact:
- Site 0015
-
Madrid, Spain, 28041
- Not yet recruiting
- Local Institution - 0062
-
Contact:
- Site 0062
-
Málaga, Spain, 29011
- Not yet recruiting
- Local Institution - 0018
-
Contact:
- Site 0018
-
Seville, Spain, 41009
- Not yet recruiting
- Local Institution - 0008
-
Contact:
- Site 0008
-
-
A Coruña [La Coruña]
-
A Coruña, A Coruña [La Coruña], Spain, 15006
- Not yet recruiting
- Local Institution - 0007
-
Contact:
- Site 0007
-
-
Balears [Baleares]
-
Palma, Balears [Baleares], Spain, 07120
- Not yet recruiting
- Local Institution - 0011
-
Contact:
- Site 0011
-
-
Barcelona
-
Badalona, Barcelona, Spain, 08916
- Not yet recruiting
- Local Institution - 0006
-
Contact:
- Site 0006
-
-
Barcelona [Barcelona]
-
Barcelona, Barcelona [Barcelona], Spain, 08028
- Not yet recruiting
- Local Institution - 0010
-
Contact:
- Site 0010
-
-
Cantabria
-
Santander, Cantabria, Spain, 39008
- Not yet recruiting
- Local Institution - 0030
-
Contact:
- Site 0030
-
-
Madrid, Comunidad de
-
Madrid, Madrid, Comunidad de, Spain, 28034
- Not yet recruiting
- Local Institution - 0024
-
Contact:
- Site 0024
-
-
Navarre
-
Pamplona, Navarre, Spain, 31008
- Not yet recruiting
- Local Institution - 0009
-
Contact:
- Site 0009
-
-
Valenciana, Comunitat
-
Valencia, Valenciana, Comunitat, Spain, 46010
- Not yet recruiting
- Local Institution - 0084
-
Contact:
- Site 0084
-
-
-
-
-
Birmingham, United Kingdom, B9 5SS
- Not yet recruiting
- Local Institution - 0113
-
Contact:
- Site 0113
-
Leicester, United Kingdom, LE1 5WW
- Not yet recruiting
- Local Institution - 0114
-
Contact:
- Site 0114
-
-
London, City of
-
London, London, City of, United Kingdom, SE1 9RT
- Not yet recruiting
- Local Institution - 0115
-
Contact:
- Site 0115
-
-
-
-
Arizona
-
Phoenix, Arizona, United States, 85054
- Withdrawn
- Local Institution - 0005
-
-
California
-
Bellflower, California, United States, 90706
- Recruiting
- Southern California Permanente Medical Group
-
Contact:
- Gary Buchschacher, Site 0016
- Phone Number: 000-000-0000
-
Long Beach, California, United States, 90806
- Not yet recruiting
- Local Institution - 0082
-
Contact:
- Site 0082
-
-
Delaware
-
Newark, Delaware, United States, 19713
- Withdrawn
- Local Institution - 0003
-
-
Florida
-
St. Petersburg, Florida, United States, 33701
- Recruiting
- Florida Cancer Specialists - North
-
Contact:
- Maen Hussein, Site 0001
- Phone Number: 727-216-1143
-
-
Kansas
-
Wichita, Kansas, United States, 67208
- Not yet recruiting
- Local Institution - 0112
-
Contact:
- Site 0112
-
-
Massachusetts
-
Boston, Massachusetts, United States, 02215
- Not yet recruiting
- Local Institution - 0080
-
Contact:
- Site 0080
-
Boston, Massachusetts, United States, 00215
- Withdrawn
- Local Institution - 0092
-
-
Minnesota
-
Rochester, Minnesota, United States, 55905
- Recruiting
- Mayo Clinic in Rochester, Minnesota
-
Contact:
- Konstantinos Leventakos, Site 0017
- Phone Number: 507-284-2511
-
Saint Paul, Minnesota, United States, 55101
- Recruiting
- Metro-Minnesota Community Oncology Research Consortium (MMCORC)
-
Contact:
- Yan Ji, Site 0073
-
-
Nebraska
-
Omaha, Nebraska, United States, 68114
- Recruiting
- Nebraska Cancer Specialists
-
Contact:
- Mary Wells, Site 0036
- Phone Number: 531-329-3667
-
-
Oregon
-
Eugene, Oregon, United States, 97401
- Recruiting
- Oncology Associates Of Oregon, Pc
-
Contact:
- Jeff Porter Sharman, Site 0004
- Phone Number: 888-542-2525
-
-
Tennessee
-
Germantown, Tennessee, United States, 38138
- Recruiting
- The West Clinic, PLLC dba West Cancer Center
-
Contact:
- Ramakrishna Battini, Site 0023
- Phone Number: 901-683-0055
-
-
Texas
-
Bedford, Texas, United States, 76022
- Recruiting
- Texas Oncology-Bedford
-
Contact:
- Kartik Konduri, Site 0117
- Phone Number: 214-370-1000
-
Dallas, Texas, United States, 75246
- Recruiting
- Texas Oncology - Baylor Charles A. Sammons Cancer Center
-
Contact:
- Kartik Konduri, Site 0118
- Phone Number: 214-370-1000
-
Grapevine, Texas, United States, 76051
- Recruiting
- Texas Oncology - DFW
-
Contact:
- Kartik Konduri, Site 0002
- Phone Number: 214-370-1000
-
-
Washington
-
Bellingham, Washington, United States, 98225
- Not yet recruiting
- Local Institution - 0013
-
Contact:
- Site 0013
-
-
Participation Criteria
Researchers look for people who fit a certain description, called eligibility criteria. Some examples of these criteria are a person's general health condition or prior treatments.
Eligibility Criteria
Ages Eligible for Study
- Adult
- Older Adult
Accepts Healthy Volunteers
No
Description
Inclusion Criteria:
- Participant is eligible to receive continued study treatment as per the parent study, and/or investigator assessed clinical benefit.
- Individuals with assigned female sex at birth (AFSB) must have documented proof that they are not of childbearing potential. IOCBP participants who are sexually active must agree to follow the instructions for method(s) of contraception and included in the ICF.
Exclusion Criteria:
- Participant is not eligible for study treatment per the parent study eligibility criteria.
- Participants who have completed treatment with the study drugs, progressed on prior study treatment, or discontinued study treatment due to toxicity in the parent study are not eligible to receive study drug in this study.
- Participants not receiving clinical benefit from parent study drug as assessed by the investigator.
Other protocol defined inclusion/exclusion criteria applies.
Study Plan
This section provides details of the study plan, including how the study is designed and what the study is measuring.
How is the study designed?
Design Details
- Primary Purpose: Treatment
- Allocation: N/A
- Interventional Model: Parallel Assignment
- Masking: None (Open Label)
Arms and Interventions
Participant Group / Arm |
Intervention / Treatment |
|---|---|
|
Experimental: Arm B1
|
Specified dose on specified days
Specified dose on specified days
Other Names:
|
|
Experimental: Arm B2
|
Specified dose on specified days
Specified dose on specified days
Other Names:
|
|
Experimental: Arm C1
|
Specified dose on specified days
|
|
Experimental: Arm C2
|
Specified dose on specified days
|
|
Experimental: Arm A1
|
Specified dose on specified days
Other Names:
|
|
Experimental: Arm A2
|
Specified dose on specified days
Other Names:
|
|
Experimental: Arm B3
|
Specified dose on specified days
Specified dose on specified days
Other Names:
|
|
Experimental: Arm B4
|
Specified dose on specified days
Specified dose on specified days
Specified dose on specified days
Other Names:
|
|
Experimental: Arm C3
|
Specified dose on specified days
Specified dose on specified days
Other Names:
Specified dose on specified days
|
|
Experimental: Arm C4
|
Specified dose on specified days
Specified dose on specified days
Specified dose on specified days
Other Names:
|
What is the study measuring?
Primary Outcome Measures
Outcome Measure |
Time Frame |
|---|---|
|
Number of Participants With Adverse Events (AEs)
Time Frame: Up to 90 days from last dose or study discontinuation
|
Up to 90 days from last dose or study discontinuation
|
|
Number of Participants With AEs Leading to Treatment Discontinuation
Time Frame: Up to 90 days from last dose or study discontinuation
|
Up to 90 days from last dose or study discontinuation
|
|
Number of Participants With Serious Adverse Events (SAEs)
Time Frame: Up to 90 days from last dose or study discontinuation
|
Up to 90 days from last dose or study discontinuation
|
|
Number of Participants With AEs Leading to Death
Time Frame: Up to 90 days from last dose or study discontinuation
|
Up to 90 days from last dose or study discontinuation
|
Collaborators and Investigators
This is where you will find people and organizations involved with this study.
Sponsor
Investigators
- Study Director: Bristol-Myers Squibb, Bristol-Myers Squibb
Publications and helpful links
The person responsible for entering information about the study voluntarily provides these publications. These may be about anything related to the study.
Study record dates
These dates track the progress of study record and summary results submissions to ClinicalTrials.gov. Study records and reported results are reviewed by the National Library of Medicine (NLM) to make sure they meet specific quality control standards before being posted on the public website.
Study Major Dates
Study Start (Actual)
May 6, 2026
Primary Completion (Estimated)
February 16, 2028
Study Completion (Estimated)
February 16, 2028
Study Registration Dates
First Submitted
February 11, 2026
First Submitted That Met QC Criteria
February 11, 2026
First Posted (Actual)
February 17, 2026
Study Record Updates
Last Update Posted (Actual)
August 18, 2026
Last Update Submitted That Met QC Criteria
August 17, 2026
Last Verified
August 1, 2026
More Information
Terms related to this study
Additional Relevant MeSH Terms
- Amino Acids, Peptides, and Proteins
- Proteins
- Organic Chemicals
- Heterocyclic Compounds, 1-Ring
- Heterocyclic Compounds
- Heterocyclic Compounds, 2-Ring
- Heterocyclic Compounds, Fused-Ring
- Hydrocarbons
- Cycloparaffins
- Hydrocarbons, Alicyclic
- Hydrocarbons, Cyclic
- Terpenes
- Camptothecin
- Alkaloids
- Enzymes and Coenzymes
- Antibodies, Monoclonal, Humanized
- Antibodies, Monoclonal
- Antibodies
- Immunoglobulins
- Immunoproteins
- Blood Proteins
- Serum Globulins
- Globulins
- Coordination Complexes
- Guanine
- Hypoxanthines
- Purinones
- Purines
- Glutamates
- Amino Acids, Acidic
- Amino Acids
- Amino Acids, Dicarboxylic
- Taxoids
- Cyclodecanes
- Diterpenes
- Pyrimidines
- Formyltetrahydrofolates
- Tetrahydrofolates
- Folic Acid
- Pterins
- Pteridines
- Uracil
- Pyrimidinones
- Coenzymes
- Docetaxel
- Oxaliplatin
- Irinotecan
- Pemetrexed
- Cetuximab
- Fluorouracil
- Leucovorin
- pembrolizumab
- adagrasib
Other Study ID Numbers
- CA239-0071
- WHO (Other Identifier: U1111-1321-3429)
- EU CTR (Other Identifier: 2025-521908-22)
Plan for Individual participant data (IPD)
Plan to Share Individual Participant Data (IPD)?
YES
IPD Plan Description
BMS will provide access to individual anonymized participant data upon request from qualified researchers, and subject to certain criteria.
Additional information regarding Bristol Myer Squibb's data sharing policy and process can be found at https://www.bms.com/researchers-and-partners/clinical-trials-and-research.html
IPD Sharing Time Frame
See Plan Description
IPD Sharing Access Criteria
See Plan Description
IPD Sharing Supporting Information Type
- STUDY_PROTOCOL
- SAP
- CSR
Drug and device information, study documents
Studies a U.S. FDA-regulated drug product
Yes
Studies a U.S. FDA-regulated device product
No
This information was retrieved directly from the website clinicaltrials.gov without any changes. If you have any requests to change, remove or update your study details, please contact register@clinicaltrials.gov. As soon as a change is implemented on clinicaltrials.gov, this will be updated automatically on our website as well.